Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000819151 | SCV000959795 | pathogenic | Spastic paraplegia | 2024-01-02 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser145*) in the SACS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SACS are known to be pathogenic (PMID: 18465152, 20876471). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with SACS-related conditions. ClinVar contains an entry for this variant (Variation ID: 661678). For these reasons, this variant has been classified as Pathogenic. |
Athena Diagnostics | RCV000992789 | SCV001145333 | likely pathogenic | not provided | 2019-07-08 | criteria provided, single submitter | clinical testing | The variant creates a premature nonsense codon, and is therefore predicted to result in the loss of a functional protein. Frequency data from large databases are of low quality and therefore uninformative. |
Genome- |
RCV001785730 | SCV002027676 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001785730 | SCV002811452 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000992789 | SCV003194935 | pathogenic | not provided | 2023-01-17 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 35303589) |
Prevention |
RCV003396439 | SCV004104543 | likely pathogenic | SACS-related disorder | 2023-06-02 | criteria provided, single submitter | clinical testing | The SACS c.434C>G variant is predicted to result in premature protein termination (p.Ser145*). To our knowledge, this variant has not been reported in affected individuals. This variant is reported in 0.0065% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/13-23939328-G-C). Nonsense variants in SACS are expected to be pathogenic. This variant is interpreted as likely pathogenic. |
Baylor Genetics | RCV001785730 | SCV004209924 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2023-08-27 | criteria provided, single submitter | clinical testing |